Ischaemic stroke patients with heterozygous factorV Leiden present with multiple brain infarctions and widespread atherothrombotic disease

Thrombosis and Haemostasis

Volumn 101, Issue 1, 2009, Pages 145-150

  Haapaniemi, Elena ^a   Helenius, Johanna ^a   Jakovljević, Dimitrije ^a   Soinne, Lauri ^a   Syrjälä, Martti ^a   Kaste, Markku ^a   Lassila, Riitta ^a   Tatlisumak, Turgut ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cardiovascular disease; Coagulation; FactorV Leiden mutation; Ischaemic stroke; Peripheral arterial occlusive disease

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 5 LEIDEN; WARFARIN; BLOOD CLOTTING FACTOR 5;

ADULT; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SCORING SYSTEM; BRAIN ISCHEMIA; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; REGISTER; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOSIS; TIME;

ADULT; ARTERIAL OCCLUSIVE DISEASES; BRAIN INFARCTION; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PHENOTYPE; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOSIS; TIME FACTORS;

EID: 60849115859     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-12-0754     Document Type: Article

References (44)

1. Bertina R, Koeleman B, Koster T, et al. Mutation in blood eoagulation factor V associated with resistance to activated protein C, Nature 1994; 369: 64-67.
2. Dahlbäck B. Activated protein C resistance and thrombosis: molecular mechanism of hypercoagulable state due to FVR506Q mutation, Semin Thromb Hemost 1999; 25: 273-289,
3. Kim R, Becker R, Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-957.
4. Marcucci R, Sofi R, Fedi S, et al. Thrornbophilic risk factors in patients with severe carotid atherosclerosis. J Thromb Haemosl 2005; 3: 502-507.
5. Juul K, Tybjærg-Hansen A, Steffensen R, et al. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
6. Casas J, Hingorani A, Bautista L, et al. Male-analysis of genetic studies in ischemic stroke: thirty-two genes involvimg approximately 18,000 cases and 58,000 controls. Arch Neurol 2004; 61: 1652-1661.
7. Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 283-1288.
8. Martinelli I, Battaglioli T, Burgo I, et al. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica 2006; 91: 844-847.
9. Rosendaal F, Siscovick D, Schwartz S, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-2821.
10. Slooter A, Rosendaal F, Tanis B, et al, Prothrombotic conditions, oral contraceptives, and risk of ischemic stroke. J Thromb Haemost 2005; 3: 1213-1217.
11. Kontula K, Ylikorkala A, Miettinen H, et al. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-560.
12. Lalouschek W. Suess E, Aull S, et al. Clinical and laboratory data in heterozygous factor V Leiden mutation positive versus negative patients with TIA and minor stroke. Stroke 1995; 26: 1963-1964.
13. Zunker P, Hohenstein C, Plendl H-J, et al. Activated protein C resistance and acute ischemic stroke: relation to stroke causation and age. J Neurol 2001; 248: 701-704.
14. Hankey G, Eikelboom J, van Bockxmeer F, et al. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001: 32: 1793-1799.
15. Goldstein L, Adams R, Alberts M, et al. Primary prevention of ischemic stroke. Stroke 2006; 37: 1583-1633.
16. European stroke initiative recommendations for stroke management-update 2003. Cerebrovasc Dis 2003; 16:311-337.
17. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526.
18. Blennow K, Wallin A, Uhlemann C, et al. Whitematter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand 1991; 83: 187-193,
19. Szolnoki Z, Samogyvári F, Kondacs A, et al. Evalution of the interactions of common genetic mutations in stroke patients. J Neurol 2002; 249: 1391-1397.
20. Haapaniemi E, Tatlisumak T, Soinne L, et al. Natural anticoagulants (antithrombin III, protein C, and protein S) in patients with mild to moderate ischemic stroke. Acta Neurol Scand 2002; 105: 107-114.
21. Haapaniemi E, Helenius J, Soinne L, et al. Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke. Eur J Neurol 2007: 14:12-17.
22. Gruber A, Griffin J. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-2348.
23. Sampram E, Lindblad B, Dahlbäck B. Activated protein C resistance in patients with peripheral vascular disease. J Vase Surg 1998; 28: 624-629.
24. Reny J, Alhenc-Gelas M, Fontana P, et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease results of a case-control study. J Thromb Haemost 2004; 2: 1334- 1340.
25. Mueller T, Marschon R, Dieplinger B, et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LTPAD) study, J Vase Surg 2005; 41:808-815.
26. Sofi F, Lari B, Rogolino A, et al. Thrornbophilic risk factors for symptomatic peripheral arterial disease. J Vase Surg 2005; 41: 255-260.
27. Gardemann A, Arsic T, Katz N, et al. The factor II G20210 A and factor V G1691A gene transitions and coronory heart disease. Thromb Haemost 1999; 81: 208-213.
28. Mansourati J, Da Cosla A, Munier S, et al. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83: 822-825.
29. Voetsch B, Damasceno B, Camargo E, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adult. Thromb Haemost 2000; 83: 229-233.
30. Ye Z, Liu E, Higgins J, et al. Seven haemostatic gene polymorphisms in coronory disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367:651-658.
31. Eskandari M, Bontempo F, Hassett A, et al. Arterial thromboembolie events in patients with the factor V Leiden mutation. Am J Surg 1998; 176: 122-125.
32. Rallidis L, Belesi C, Manioudaki H, et al. Myocadrial infarction under the age of 36: prevalence of thrombophilic disorders. Thromb Haem1ost 2003; 90: 272-279.
33. Glueck C, Wang P, Fontaine R, et al. Estrogen replacement therapy thrombophilia, and atherothrombosis. Metabolism 2002; 51: 724-732.
34. Hobikoglu G, Akyuz U, Akyuz F, et al. Factor V Leiden is a risk factor for myocardial infarction in young Turkish men. Acta Cardiol 2004; 59: 594-597.
35. Sabino A, Ribeiro D, Carvalho M, et al. Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis 2006; 17:271-275.
36. Willeit J, Kiechl S, Oberhollenzer F, et al. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol 2000; 20: 529-537.
37. Provenzale J, Barboriak D, Davey I, et al. Cerebrovascular disease risk factors: neuroradiology findings in patients with activated protein C resistance. Radiology 1998;207:85-89.
38. Szolnoki Z, Somogyvari F. Kondacs A, et al. Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischemic stroke. J Neurol 2001; 248: 756-761.
39. Adachi T, Kobayashi S, Yamaguchi S: Frequency and pathogenesis of silent subcortical brain infarction in acute first-ever ischemic stroke. Intern Med 2002; 41: 103-108.
40. Pohjasvaara T, Mäntylä R, Aronen H, et al. Clinical and radiological determinations of prestroke cognitive decline in a stroke cohort. J Neurol Neurosurg Psychiatry 1999;67:742-748.
41. Mok V, Wong A, Lam W, et al. Cognitive impairment and functional outcome after stroke associated with small vessel disease. J Neurol Neurosurg Psychiatry 2004; 75: 560-566.
42. Vermeer S, Longstreth Jr W, Koudstaal P. Silent brain infarcts: a systematic review. Lancet Neurol 2007;6:611-619.
43. Knuiman M, Folsom A, Chambless L, et al. Association of hemostatic variables with MRI-detected cerebral abnormalities: the atherosclerosis risk in communities study. Neuroepidemiology 2001; 20: 96-104.
44. Pruissen D, Kappelle L, Algra A. Polymorphisms and risk of ischemic stroke (POLARIS) study: rationale and design. Eur Neurol 2004; 51: 30-34.